At close: December 13 at 4:00:02 PM EST
After hours: December 13 at 5:58:08 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
20,811.00
207,573.00
-99,303.00
-54,238.00
-28,662.00
Investing Cash Flow
-157,908.00
-154,512.00
-117,674.00
-79,976.00
-888.00
Financing Cash Flow
170,521.00
279,163.00
252,625.00
118,451.00
41,656.00
End Cash Position
164,472.00
398,904.00
66,680.00
31,032.00
46,795.00
Income Tax Paid Supplemental Data
1,467.00
212.00
--
--
--
Capital Expenditure
-17,228.00
-21,428.00
-2,277.00
-5,783.00
-888.00
Issuance of Capital Stock
199,706.00
299,706.00
259,833.00
119,118.00
42,801.00
Repayment of Debt
-44,688.00
-29,392.00
-9,675.00
-387.00
--
Repurchase of Capital Stock
--
--
--
-24.00
--
Free Cash Flow
3,583.00
186,145.00
-101,580.00
-60,021.00
-29,550.00
12/31/2020 - 2/4/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
LEGN Legend Biotech Corporation
35.12
-1.04%
ANAB AnaptysBio, Inc.
15.59
+3.79%
BCYC Bicycle Therapeutics plc
13.81
-31.33%
NUVL Nuvalent, Inc.
86.86
+0.05%
NRIX Nurix Therapeutics, Inc.
20.27
-1.41%
SLRN Acelyrin, Inc.
3.2300
-8.76%
KURA Kura Oncology, Inc.
9.63
-0.62%
MRUS Merus N.V.
42.83
+3.33%
APGE Apogee Therapeutics, Inc.
44.50
+0.41%
JANX Janux Therapeutics, Inc.
61.11
-0.63%